Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - cefalexin monohydrate - tablets - 250 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - cefalexin monohydrate - tablets - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - cefalexin - granules effervescent - 50 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalotin, quantity: 1 g - injection, powder for - excipient ingredients: sodium bicarbonate - keflin is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. culture and susceptibility studies should be performed. therapy may be instituted before results of susceptibility studies are obtained (see notes under microbiology). respiratory tract infections caused by s. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group a beta-haemolytic streptococci, klebsiella, and h. influenzae. skin and soft-tissue infections, including peritonitis, caused by staphylococci (penicillinase and non-penicillinase-producing), group a beta-haemolytic streptococci, e. coli, pr. mirabilis, and klebsiella. genito-urinary tract infections caused by e. coli, pr. mirabilis and klebsiella. septicaemia, including endocarditis, caused by s. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group a beta-haemolytic streptococci, s. viridans; e. coli, pr. mirabilis, and klebsiella. bone and joint

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalotin -

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - refexxin is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibio

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - refexxin is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibio